scout
Opinion|Videos|March 13, 2025

RATIONALE-305: Exploring Adverse Event Profile

Panelists discuss how the RATIONALE-305 trial revealed a manageable adverse event profile for tislelizumab plus chemotherapy despite increased rates of neutropenia and anemia compared to placebo plus chemotherapy in advanced gastric cancer patients.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME